Immunotherapy has revolutionized melanoma treatment over the past 15 years, but a stubborn problem persists: many patients eventually stop responding to these powerful drugs. As researchers gather this week for major cancer conferences, they're unveiling new strategies to overcome resistance, including combination therapies and next-generation immune-boosting approaches that could extend survival for patients whose tumors have become resistant to standard checkpoint inhibitors.

What Happens When Melanoma Becomes Resistant to Immunotherapy?

Immunotherapy works by releasing the brakes on the immune system, allowing T cells to recognize and destroy cancer cells. Checkpoint inhibitors like nivolumab and pembrolizumab target proteins called PD-1 and PD-L1 that normally keep the immune system in check. For some melanoma patients, this approach delivers remarkable results. However, resistance develops in two distinct patterns.

Primary resistance occurs when tumors never shrink in the first place, while acquired resistance develops after an initial response followed by tumor regrowth. Both patterns reflect the tumor's ability to evolve and hide from the immune system. Understanding these mechanisms has become central to developing better treatments.

How Are Researchers Overcoming Melanoma Resistance?

The Parker Institute for Cancer Immunotherapy is presenting over 50 studies at the American Society of Clinical Oncology (ASCO) Annual Meeting this week, with several focusing on melanoma resistance. The approaches being tested include:

• Dual Checkpoint Blockade: Combining two different checkpoint inhibitors to attack the immune system's brakes from multiple angles. A five-year update of nivolumab plus relatlimab in advanced melanoma shows sustained benefit in some patients, with researchers also comparing this combination to nivolumab plus ipilimumab.
• Novel Immune Targets: Moving beyond PD-1 and PD-L1 to target alternative checkpoints like LAG-3, TIGIT, and TIM-3. The RELATIVITY-047 study demonstrated that combined LAG-3 and PD-1 blockade improved progression-free survival compared with PD-1 inhibition alone in melanoma.
• Engineered Cell Therapies: Using tumor-infiltrating lymphocytes (TILs), which are immune cells extracted from the tumor itself and engineered to be more powerful. Phase 2 results of engineered TIL therapy with regulatable membrane-bound IL-15 in advanced melanoma after checkpoint inhibitor progression are being presented this week.
• Combination with Other Drug Classes: Pairing checkpoint inhibitors with antibody-drug conjugates (ADCs), which deliver toxic payloads directly to cancer cells. Phase 2 results in patients with advanced cutaneous melanoma refractory or resistant to anti-PD-(L)1 therapy are being unveiled.
• Brain Metastasis Strategies: Addressing melanoma that spreads to the brain, which is particularly difficult to treat. A multicenter Phase 2 trial of relatlimab, nivolumab, and ipilimumab in patients with asymptomatic and symptomatic melanoma brain metastases is underway.

The breadth of these approaches reflects a fundamental shift in cancer immunotherapy strategy. Rather than relying on a single drug, researchers are increasingly convinced that combinations will be necessary to achieve durable responses and prevent resistance.

"Cancer continues to demand urgency, and the PICI Network is designed to meet that challenge through coordinated, collaborative science," said Dr. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy.

Dr. Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy

Why Is Resistance So Common in Melanoma?

Tumors develop resistance through several biological mechanisms. One of the most important involves loss of antigen presentation machinery. When tumors lose a protein called beta-2-microglobulin (B2M), they can no longer display the molecular signals that T cells use to recognize them. Under the pressure of immunotherapy, tumors essentially learn to hide from the immune system.

Another mechanism involves T-cell exhaustion. Even when checkpoint inhibitors remove the brakes on T cells, persistent exposure to tumor antigens can cause these immune cells to become exhausted and unable to function effectively. This exhaustion is marked by expression of multiple inhibitory receptors including TIGIT, LAG-3, and TIM-3, which is why targeting these alternative checkpoints has become so promising.

The tumor microenvironment also plays a critical role. Some melanomas are inherently "immune-cold," meaning they have few T cells infiltrating the tumor. These tumors often have low expression of PD-L1, the protein that checkpoint inhibitors target. Researchers now view low PD-L1 expression not as an isolated finding but as a marker of broader immune dysfunction within the tumor.

What Does This Mean for Melanoma Patients?

The rapid expansion of immunotherapy options offers hope for patients whose tumors have become resistant to standard treatments. Over the past 15 years, the field has moved from a single checkpoint inhibitor approach to a rich pipeline of combination strategies. Researchers estimate there are now over 2,500 drugs and programs for cancer immunotherapy in development.

The key takeaway is that no single immunotherapy approach works for everyone. Some patients benefit from dual checkpoint blockade, while others may respond better to engineered cell therapies or combinations with other drug classes. As more data emerges from ongoing trials, oncologists will have increasingly sophisticated tools to match patients with the treatments most likely to work for their specific tumor biology.

The convergence of these strategies represents a fundamental principle in modern cancer treatment: combinations are more powerful than single agents. By attacking cancer through multiple immune pathways simultaneously, researchers hope to overcome the adaptive resistance that has limited the long-term success of checkpoint inhibitors alone.